On March 10, 2022 Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, reported an in-person poster presentation will be given at the American Academy of Cancer Research (AACR) (Free AACR Whitepaper) on its lead candidate, PT-112, and how it selectively induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines (Press release, Phosplatin, MAR 10, 2022, View Source [SID1234609876]). The presentation will be held at the 2022 AACR (Free AACR Whitepaper) Annual Meeting taking place on April 8-13, 2022 in New Orleans.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The work to be presented was generated by the company under a research collaboration with the Anel Lab at the University of Zaragoza, Spain. The characterization of intracellular pathways leading to ICD and the adaptive immune response is an important research aim of the company, and a related peer-reviewed manuscript is under preparation.

Presentation Title: "PT-112 induces potent mitochondrial stress and immunogenic cell death in human prostate cancer cell lines"
Lead Author: R. Soler, University of Zaragoza/Aragón Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain
Session Category: Experimental and Molecular Therapeutics
Session: Mechanisms of Drug Action 3
Session Date / Time: Monday, April 11, 2022 from 9:00am – 12:30pm CST
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 24
Poster Number: 5

The presentation will be available both in person and online in Proceedings of the AACR (Free AACR Whitepaper) through the conference website.

For more information about Phosplatin’s clinical trials, visit the website at www.Phosplatin.com.

About PT-112

PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 may represent the best-in-class inducer of this immunological form of cancer cell death. Further, PT-112 harbors a property known as osteotropism, or the propensity of the drug to reach its highest concentrations in certain areas of the bone, making it a candidate for treatment of patients with cancers that originate in, or metastasize to, the bone. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO (Free ESMO Whitepaper) 2018 Annual Congress. The combination Phase 1b dose escalation study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO (Free ESMO Whitepaper) 2020 Virtual Congress. The Phase 1 study in patients with relapsed or refractory multiple myeloma presented at ASH (Free ASH Whitepaper) is the third completed Phase 1 study of PT-112. Monotherapy Phase 2 development is ongoing in mCRPC, and the PD-L1 combination study is ongoing in a dose confirmation cohort of non-small cell lung cancer (NSCLC) patients, and will soon include the Phase 2 proof of concept study in thymic epithelial tumors under the company’s collaboration with the NCI.